Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of BMS-986435 in Hepatic Impairment
NCT07248839Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986435 in hypertrophic cardiomyopathy (HCM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration at Day 45, Area under the concentration-time curve from time zero to time of last quantifiable concentration at Day 45 and 1 more. Started Dec 2025; status: completed.
02
Drugs
BMS-986435
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07248839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07248839.